A1362
Agomelatine
≥98% (HPLC)
Synonym(s):
N-[2-(7-Methoxy-1-naphthalenyl)ethyl]-acetamide, S-20098
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C15H17NO2
CAS Number:
Molecular Weight:
243.30
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to off-white
solubility
DMSO: >50 mg/mL
originator
Servier
storage temp.
2-8°C
SMILES string
COc1ccc2cccc(CCNC(C)=O)c2c1
InChI
1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)
InChI key
YJYPHIXNFHFHND-UHFFFAOYSA-N
Gene Information
human ... HTR2C(3358), MTNR1A(4543), MTNR1B(4544)
Application
Agomelatine has been used:
- to study its effects on adult neurogenesis and hippocampus apoptosis using the stress-induced depression model of rats
- to explore its effects on tau protein phosphorylation and to study its neuroprotective mechanism
- to study its effects on intracellular calcium ([Ca2+]i) signaling in peripheral neurons of rat dorsal root ganglion (DRG) neurons
Biochem/physiol Actions
Agomelatine modulates the sleep-wake cycle through its chronobiotic activity. It normalizes the sleep pattern in patients suffering from depression and seasonal mood disorder.
Agomelatine is an extremely potent agonist at both melatonin receptors (MT1 and MT2), with additional antagonism at 5HT2C.
Agomelatine is an extremely potent agonist at both melatonin receptors (MT1 and MT2), with additional antagonism at 5HT2C. It is a novel antidepressant with many desired in vivo properties, including neuroprotection and neurogenesis in depression-sensitive brain areas. Agomelatine′s efficacy appears to be due to both melatonergic and serotonergic properties. In neurogenesis assays, both in vitro and in vivo, the compound effects were differentially affected by antagonists for MT1/MT2 and 5HT2C, demonstrating actions through all three receptors.
Features and Benefits
This compound is featured on the Melatonin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Servier. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
pcodes
Hazard Classifications
Aquatic Acute 1 - Aquatic Chronic 1
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Two cases of delirium with agomelatine therapy.
María Gabriela Viejo Sacha et al.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 25(1), 67-68 (2013-02-05)
Laurence Lanfumey et al.
Pharmacology & therapeutics, 138(2), 176-184 (2013-01-26)
Affective disorders such as major depression, bipolar disorders and seasonal affective disorders have been described as alterations of various neuronal systems. In addition to the classical monoaminergic hypotheses that have been long proposed to explain the pathophysiology of these disorders
[Approaches to treatment optimization of depression in patients with Parkinson's disease].
E Ya Strashunskaya et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 113(4), 75-79 (2013-06-07)
Global Trade Item Number
| SKU | GTIN |
|---|---|
| A1362-25MG | 04061832555331 |
| A1362-5MG | 04061832555348 |